Limits...
Safety and efficacy of entecavir for the treatment of chronic hepatitis B.

Osborn M - Infect Drug Resist (2011)

Bottom Line: Entecavir is a cyclopentyl deoxyguanosine analog that was approved for the treatment of the hepatitis B virus (HBV) in 2005.Safety and efficacy have been established in compensated cirrhosis and HIV-coinfected patients.Studies in decompensated cirrhosis also show efficacy.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.

ABSTRACT
Entecavir is a cyclopentyl deoxyguanosine analog that was approved for the treatment of the hepatitis B virus (HBV) in 2005. In Phase III trials, it showed potent HBV suppression with drops of 6- to 7-log copies/mL in HBV DNA at 1 year. In addition, rates of genotypic resistance in nucleos(t)ide-naïve patients are low, reaching only 1.2% after 6 years. Safety and efficacy have been established in compensated cirrhosis and HIV-coinfected patients. Studies in decompensated cirrhosis also show efficacy. Because of potent viral suppression and a large genetic barrier to resistance, entecavir is now a first-line choice in most HBV treatment guidelines and has become an integral part of the HBV treatment armamentarium.

No MeSH data available.


Related in: MedlinePlus

Resistance rates of available nucleos(t)ide analogs in hepatitis B patients. Note that no tenofovir resistance has been seen through 4 years of follow-up.31,36–42Abbreviations: e+, hepatitis B e-antigen positive; e−, hepatitis B e-antigen negative; lam-ref, lamivudine refractory.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108748&req=5

f1-idr-4-055: Resistance rates of available nucleos(t)ide analogs in hepatitis B patients. Note that no tenofovir resistance has been seen through 4 years of follow-up.31,36–42Abbreviations: e+, hepatitis B e-antigen positive; e−, hepatitis B e-antigen negative; lam-ref, lamivudine refractory.

Mentions: One disadvantage of nucleos(t)ide analogs is development of antiviral resistance with prolonged use. Resistance is accompanied by virologic and biochemical breakthrough, and, in rare cases, hepatic decompensation and death.34,35 Rates of lamivudine resistance exceed 70% by year 4 of treatment,36 limiting its usefulness for first-line therapy. Resistance rates for adefovir and telbivudine are lower, yet still clinically significant (Figure 1). Tenofovir resistance has not yet been well defined but appears to be rare, as no signature mutation has been defined and genotypic resistance through 4 years of therapy has not been reported.41


Safety and efficacy of entecavir for the treatment of chronic hepatitis B.

Osborn M - Infect Drug Resist (2011)

Resistance rates of available nucleos(t)ide analogs in hepatitis B patients. Note that no tenofovir resistance has been seen through 4 years of follow-up.31,36–42Abbreviations: e+, hepatitis B e-antigen positive; e−, hepatitis B e-antigen negative; lam-ref, lamivudine refractory.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108748&req=5

f1-idr-4-055: Resistance rates of available nucleos(t)ide analogs in hepatitis B patients. Note that no tenofovir resistance has been seen through 4 years of follow-up.31,36–42Abbreviations: e+, hepatitis B e-antigen positive; e−, hepatitis B e-antigen negative; lam-ref, lamivudine refractory.
Mentions: One disadvantage of nucleos(t)ide analogs is development of antiviral resistance with prolonged use. Resistance is accompanied by virologic and biochemical breakthrough, and, in rare cases, hepatic decompensation and death.34,35 Rates of lamivudine resistance exceed 70% by year 4 of treatment,36 limiting its usefulness for first-line therapy. Resistance rates for adefovir and telbivudine are lower, yet still clinically significant (Figure 1). Tenofovir resistance has not yet been well defined but appears to be rare, as no signature mutation has been defined and genotypic resistance through 4 years of therapy has not been reported.41

Bottom Line: Entecavir is a cyclopentyl deoxyguanosine analog that was approved for the treatment of the hepatitis B virus (HBV) in 2005.Safety and efficacy have been established in compensated cirrhosis and HIV-coinfected patients.Studies in decompensated cirrhosis also show efficacy.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.

ABSTRACT
Entecavir is a cyclopentyl deoxyguanosine analog that was approved for the treatment of the hepatitis B virus (HBV) in 2005. In Phase III trials, it showed potent HBV suppression with drops of 6- to 7-log copies/mL in HBV DNA at 1 year. In addition, rates of genotypic resistance in nucleos(t)ide-naïve patients are low, reaching only 1.2% after 6 years. Safety and efficacy have been established in compensated cirrhosis and HIV-coinfected patients. Studies in decompensated cirrhosis also show efficacy. Because of potent viral suppression and a large genetic barrier to resistance, entecavir is now a first-line choice in most HBV treatment guidelines and has become an integral part of the HBV treatment armamentarium.

No MeSH data available.


Related in: MedlinePlus